Evidence map›Paper›PMID 41142815›Full record

ReviewFrontiers in immunology2025

From essential basic understanding to clinical application - biological, physical and pathophysiological principles of (low-dose) radiotherapy in benign diseases.

Lisa Deloch, David Rene Steike, Felix Pascher, Anne-Marie Thole, Maya Shariff, Jan Kriz, Mathias Sonnhoff, Robert Blach, Angel Montero, Friedrich Paulsen and 13 more

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lisa Deloch *Department of Radiation Oncology, Uniklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
David Rene Steike *Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
Felix PascherDepartment of Radiation Oncology, Alexianer Clemenshospital Muenster, Muenster, Germany.
Anne-Marie TholeRadioOnkologieNetzwerk, Radiation Therapy Osnabrueck, Osnabrueck, Germany.
Maya ShariffDepartment of Radiation Oncology, Uniklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Jan KrizDepartment of Radiation Oncology, Alexianer Clemenshospital Muenster, Muenster, Germany.
Mathias SonnhoffDepartment of Radiotherapy, Hannover Medical School, Hannover, Germany.
Robert BlachDepartment of Radiotherapy, Hannover Medical School, Hannover, Germany.
Angel MonteroDepartment of Radiation Oncology, HM Hospitales, Madrid, Spain.
Friedrich PaulsenInstitute of Functional and Clinical Anatomy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Eileen SocherInstitute of Functional and Clinical Anatomy, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Silvia Gomez OrdonezClinic for Radio-Oncology, City Hospital Triemli, Zürich, Switzerland.
Horacio Ayala GaonaDepartment of Radiation Oncology, Uniklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Ralph MueckeRadiotherapy RheinMainNahe, Mainz-Ruesselsheim-Bad Kreuznach, Bad Kreuznach, Germany.
Bobby KoneruDepartment of Radiation Oncology, Stritch School of Medicine, Cardinal Bernadin Cancer Center, Loyola University Chicago, Maywood, IL, United States.
Richard ShafferGenesisCare UK, Department of Radiation Oncology, Cromwell Hospital, London, United Kingdom.
Philipp SchubertDepartment of Radiation Oncology, Uniklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Florian PutzDepartment of Radiation Oncology, Uniklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Mark TrombettaDivision of Radiation Oncology, Allegheny General Hospital, Drexel University College of Medicine, Pittsburgh, PA, United States.
Hans T EichDepartment of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
Oliver OttDepartment of Radiation Oncology, Uniklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Rainer FietkauDepartment of Radiation Oncology, Uniklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Thomas WeissmannDepartment of Radiation Oncology, Uniklinik Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low dose radiotherapy (LDRT) is a radiation technique in the treatment of benign conditions to relieve symptoms and improve mobility and pain with minimal overall side effects. There are many reports describing the use of LDRT in the treatment of osteoarthritis (OA), tendinitis and hyperproliferative disorders. The targeted diseases are complex and multifactorial, characterized by inflammation, cellular alterations, and tissue degeneration, affecting millions of people worldwide with increasing prevalence due to aging populations. However, an understanding of the pathophysiological mechanisms as well as the underlying biological and physical mechanisms is important for the clinical-practical application, as a foundation for empirical clinical studies and state-of-the-art patient treatment. In this review, we provide an overview of the broad use of LDRT in the treatment of benign diseases with well-described and illustrated overviews of the pathomechanisms of OA, tendinitis, bursitis, benign fibromatoses and hyperproliferative diseases. The biological, physical, and molecular mechanisms behind it are also described. We further provide a broad overview of studies as well as current discussions of the therapy such as risk assessment, treatment frequency and dosage, along with future perspectives to improve clinical application overall. Taken together, this review illustrates the multifaceted application of (LD)RT, emphasizing that each disease requires a unique treatment approach due to the wide variation in pathology, biological mechanisms, target volumes, and organs at risk, but it also highlights the need for well-designed (placebo)-controlled studies in a range of indications.

Indexed as

OsteoarthritisRadiotherapyTendinopathyAnimalsBursitisHumansRadiotherapy Dosagebenign diseasesimmunologylow-dose radiotherapyosteoarthritisphysicsradiation biologyradiotherapytendinopathies

Identifiers

PMID41142815
PMCPMC12545028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.